| Literature DB >> 23896569 |
James F Kirk1, Gregg Ritter1, Isaac Finger1, Dhyana Sankar1, Joseph D Reddy1, James D Talton1, Chandra Nataraj2, Sonoko Narisawa3, José Luis Millán3, Ronald R Cobb1.
Abstract
Collagen scaffolds have been widely employed as a dermal equivalent to induce fibroblast infiltrations and dermal regeneration in the treatment of chronic wounds and diabetic foot ulcers. Cross-linking methods have been developed to address the disadvantages of the rapid degradation associated with collagen-based scaffolds. To eliminate the potential drawbacks associated with glutaraldehyde cross-linking, methods using a water soluble carbodiimide have been developed. In the present study, the glycosaminoglycan (GAG) hyaluronic acid (HA), was covalently attached to an equine tendon derived collagen scaffold using 1-ethyl-3-(3-dimethyl aminopropyl) carbodiimide (EDC) to create ntSPONGE The HA was shown to be homogeneously distributed throughout the collagen matrix. In vitro analyses of the scaffold indicated that the cross-linking enhanced the biological stability by decreasing the enzymatic degradation and increasing the thermal denaturation temperature. The material was shown to support the attachment and proliferation of mouse L929 fibroblast cells. In addition, the cross-linking decreased the resorption rate of the collagen as measured in an intramuscular implant model in rabbits. The material was also shown to be biocompatible in a variety of in vitro and in vivo assays. These results indicate that this cross-linked collagen-HA scaffold, ntSPONGE has the potential for use in chronic wound healing.Entities:
Keywords: collagen sponge; cross-linking; histology; hyaluronic acid; wound repair
Mesh:
Substances:
Year: 2013 PMID: 23896569 PMCID: PMC3866196 DOI: 10.4161/biom.25633
Source DB: PubMed Journal: Biomatter ISSN: 2159-2527
Table 1. Criteria for evaluating cytotoxicity
| Grade | Reactivity | Conditions of Culture |
|---|---|---|
| 0 | None | Discreet intracytoplasmic granules; no cell lysis |
| 1 | Slight | Not more than 20% of the cells are round, loosely attached, and without intracytoplasmic granules; occasional lysed cells are present |
| 2 | Mild | Not more than 50% of the cells are round and devoid of intracytoplasmic granules; no extensive cell lysis and empty areas between cells |
| 3 | Moderate | Not more than 70% of the cell layers contain rounded cells and/or lysed |
| 4 | Severe | Nearly complete destruction of the cell layers |
Table 2. Cytotoxicity of ntSPONGE™
| Test Article/Treatment | | ||
|---|---|---|---|
| 24 h | 48 h | 72 h | |
| Test Article 1:2 Dilution | 0/0/0 | 1/1/1 | 1/1/1 |
| Test Article 1:4 Dilution | 0/0/0 | 0/0/0 | 0/0/0 |
| Test Article 1:8 Dilution | 0/0/0 | 0/0/0 | 0/0/0 |
| Test Article 1:16 Dilution | 0/0/0 | 0/0/0 | 0/0/0 |
| Positive Control | 4/4/4 | 4/4/4 | 4/4/4 |
| Intermediate Control | 2/2/2 | 2/2/2 | 2/2/2 |
| Negative Control | 0/0/0 | 0/0/0 | 0/0/0 |
| Cell Control | 0/0/0 | 0/0/0 | 0/0/0 |
Summary of cytotoxicity scores for ntSPONGETM and empty syringe assembly extracts in L-929 cell culture.
Table 3A. Genotoxicity/Mutagenicity of ntSPONGE™
| Strain | ntSPONGETM NS Extract | NS | ntSPONGETM DMSO Extract | DMSO | 2-AA |
|---|---|---|---|---|---|
| TA97a | 138.3 | 152 | 141.3 | 136.3 | 2163 |
| TA98 | 33.7 | 32.7 | 32.7 | 33.3 | 1933.3 |
| TA100 | 104.7 | 118 | 104.7 | 102 | 1122.3 |
| TA1535 | 18 | 13.7 | 12.7 | 15 | 140 |
| WP2-uvrA- | 19.3 | 20 | 16 | 21.3 | 256.7 |
Average colony counts (n = 3) for the strains of S. typhimurium used in the Ames Assay in the presence or absence of ntSPONGETM extract or 2-AA with S9 activation.
Genotoxicity/Mutagenicity of ntSPONGE™
| Strain | ntSPONGETM NS Extract | NS | ntSPONGETM DMSO Extract | DMSO | Mutagen |
|---|---|---|---|---|---|
| TA97a | 90.7 | 112.3 | 108.7 | 94 | ICR-191 (1045.7) |
| TA98 | 31 | 31 | 29.3 | 25 | 2-NF (1055.7) |
| TA100 | 116.7 | 115 | 95.7 | 115.7 | Na Azide (901.7) |
| TA1535 | 15.7 | 18.7 | 11.7 | 16 | Na Azide (364.7) |
| WP2-uvrA- | 19.7 | 23.7 | 21.7 | 19.3 | MNNG (108) |
Average colony counts (n = 3) for the strains of S. typhimurium used in the Ames Assay in the presence or absence of ntSPONGETM extract or a direct-acting without S9 activation.
Table 4. Mouse Lymphoma Assay
| Treatment | Device Extract NS | Device Extract DMSO | Vehicle Control NS | Vehicle Control DMSO | 5 μγ/ml MMS | 15 μg/ml MMS | 3 μg/ml CP | 5 μg/ml CP |
|---|---|---|---|---|---|---|---|---|
| 45.9 | 46.1 | 49.5 | 44.8 | 199.5 | 390.0 | N/A | N/A | |
| 40.6 | 35.1 | 47.1 | 73.1 | N/A | N/A | 276.2 | 490.8 |
Mutant frequency (x10−6)
Table 5. Acute Systemic Toxicity of ntSPONGE™
| Extract | Fatalities | Clinical Signs of Toxicity | > 10% Body Weight Loss | |||
|---|---|---|---|---|---|---|
| ntSPONGE | Control | ntSPONGETM | Control | ntSPONGETM | Control | |
| 0/5 | 0/5 | 0/5 | 0/5 | 0/5 | 0/5 | |
| 0/5 | 0/5 | 0/5 | 0/5 | 0/5 | 0/5 | |
Fatalities, toxicity signs, and weight loss greater than 2 g in mice systemically exposed to ntSPONGETM and control extracts.
Table 6A. Clinical Observations of Subacute Intraperitoneal Toxicity
| Group | Fatalities | Clinical Signs of Toxicity | Abnormal Lesions Noted at Necropsy | |||
|---|---|---|---|---|---|---|
| ntSPONGE | Control | ntSPONGETM | Control | NntSPONGETM | Control | |
| 0/5 | 0/5 | 0/5 | 0/5 | *5/5 | *5/5 | |
| 0/5 | 0/5 | 0/5 | 0/5 | *5/5 | *5/5 | |
White spots were noted throughout the abdomen.
Mean + Standard Deviation Body Weight and Body Weight Change (g) of Subacute Intraperitoneal Toxicity
| Article | Male | Female | ||||
|---|---|---|---|---|---|---|
| Day 0 | Day 14 | Change | Day 0 | Day14 | Change | |
| 24.4 ± 1.68 | 32.7 ± 2.15 | 8.4 ± 1.45 | 21.3 ± 0.90 | 24.2 ± 1.25 | 2.9 ± 1.15 | |
| 24.5 ± 1.26 | 32. ± 0.54 | 8.2 ± 0.99 | 21.3 ± 1.17 | 23.5 ± 1.08 | 2.2 ± 0.39 | |
Table 7A. Clinical Observations of Subchronic Intravenous Toxicity
| Group | Fatalities | Clinical Signs of Toxicity | Abnormal Lesions Noted at Necropsy | |||
|---|---|---|---|---|---|---|
| ntSPONGE | Control | ntSPONGETM | Control | ntSPONGETM | Control | |
| 0/5 | 0/5 | 0/5 | 0/5 | 0/5 | 0/5 | |
| 0/5 | 0/5 | 0/5 | 0/5 | 0/5 | 0/5 | |
Table 7B. Mean + Standard Deviation Body Weight and Body Weight Change (g) of Subchronic Intravenous Toxicity
| Article | Male | Female | ||||
|---|---|---|---|---|---|---|
| Day 0 | Day 14 | Change | Day 0 | Day14 | Change | |
| 25.8 ± 2.14 | 31.8 ± 0.97 | 6.0 ± 1.55 | 21.4 ± 1.82 | 23.2 ± 1.75 | 1.8 ± 0.79 | |
| 26.1 ± 2.01 | 32.8 ± 3.59 | 6.7 ± 1.98 | 21.2 ± 1.71 | 23.0 ± 2.00 | 1.7 ± 0.87 | |

Figure 1. Cross-sectional view of ntSPONGE™ embedded with paraffin. Five micron sections were cut and then stained. (A) ntSPONGE™ stained with H&E; (B) Starting material stained with Alcian Blue; (C) ntSPONGE™ stained with Alcian Blue. Three different batches were examined and a representative slide is presented at magnification of 10x.

Figure 2. SEM of ntSPONGE™ ™ components. Three samples of each were analyzed and representative micrographs are shown. (A) Magnification of 25x; (B) Magnification of 250x

Figure 3. Ultimate tensile strength of ntSPONGE™. The results from 5 different samples were averaged and presented.
DSC Evaluations of Relative Cross-Linking Density
| Sample | Average Denaturation Temperature |
|---|---|
| 1 | 67.12°C |
| 2 | 69.56°C |
| 3 | 70.54°C |
| Control | 49.14°C |
Each sample was evaluated at least 3 times. The average denaturation temperature of the different analyses is given. The control is the non-cross-linked starting material for the ntSPONGE™ material. Samples 1–3 represent different lots of ntSPONGE™.
Table 8B. Pronase Resistance Analyses of Relative Cross-Linking Density
| Sample | Pre-Exposure (mg) | Post-Exposure (mg) | % Mass Remaining |
|---|---|---|---|
| 1 | 33.7 | 26.1 | 76.8 |
| 2 | 33.2 | 27.1 | 81.7 |
| 3 | 27.7 | 22.6 | 80.3 |
| Control | 23.8 | 0 | 0.0 |
The data are given as an average of the six replicates. The control sample was the non-cross-linked starting material. Samples 1–3 represent different lots of ntSPONGE™.

Figure 4. Cell attachment and proliferation on ntSPONGE™. Cell numbers were determined at day 3, 5, 7 and 10 d post seeding using MTT reagent. Cells were allowed to incubate with and without ntSPONGE™ material in the wells. At each timepoint, the ntSPONGE™ material was removed and counted separately (ntSPONGE™). The wells that contained the ntSPONGE™ material was also counted separately (orig. wells). (A) Mouse L929 cell proliferation on ntSPONGE™. (B) Mouse L929 cells attached directly to the ntSPONGE™. The ntSPONGE™ was removed from the wells at each time point, fixed in paraformaldehyde and stained with H&E. Representative samples are shown (magnification = 200x). Arrows refer to cells attached directly to ntSPONGE™.

Figure 5. Intramuscular Implantation of ntSPONGE™. Samples were implanted into the paravertebral muscles of New Zealand White rabbits. Animals were sacrificed and explants were removed. The muscle tissue was fixed in 10% buffered formalin and embedded with paraffin. Slides were stained with H&E and evaluated histologically. Three different samples were evaluated and a representative slide is presented (10x magnification). (A) Two week sample, non-cross-linked starting material; (B) Two week sample, ntSPONGE™; (C) Sixteen week sample, non-cross-linked starting material; (D) Sixteen week sample, ntSPONGE™ .
Table 9A. Two Week Non-Cross-linked samples of Inflammation and Tissue Response to Implant Sites
| ANIMAL NUMBER | 1 | 2 | 3 | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 1 | 2 | 3 | 4 | 5 | 1 | 2 | 3 | 4 | 5 | |
Severity Scores of Inflammation and Tissue Response to Implant Sites
| INFLAMMATION | Score | ||||
|---|---|---|---|---|---|
| 0 | 1 = Minimal | 2 = Mild | 3 = Moderate | 4 = Marked | |
| 0 | Rare, 1–5/HPF* | 6–10/HPF | Heavy Infiltrate | PAcked | |
| 0 | Rare 1–2/HPF | 3–5/HPF | Heavy Infiltrate | Sheets | |
| 0 | Minimal | Mild | Moderate | Severe | |
= High Powered Field (400x total magnification)
Table 9B. Two Week ntSPONGE™ samples of Inflammation and Tissue Response to Implant Sites
| ANIMAL NUMBER | 1 | 2 | 3 | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 1 | 2 | 3 | 4 | 5 | 1 | 2 | 3 | 4 | 5 | |
Table 9C. Sixteen Week Non-Cross-linked Samples of Inflammation and Tissue Response to Implant Sites
| ANIMAL NUMBER | 1 | 2 | 3 | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IMPLANT SITE | 1 | 2 | 3 | 4 | 5 | 1 | 2 | 3 | 4 | 5 | 1 | 2 | 3 | 4 | 5 |
| INFLAMMATION (I) | |||||||||||||||
| 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| 3 | 0 | 3 | 0 | 3 | 3 | 0 | 4 | 0 | 0 | 3 | 4 | 0 | 3 | 4 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| 2 | 0 | 1 | 3 | 3 | 3 | 0 | 3 | 0 | 0 | 0 | 1 | 0 | 0 | 3 | |
| 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Table 9D. Sixteen Week ntSPONGE™ Samples of Inflammation and Tissue Response to Implant Sites
| ANIMAL NUMBER | 1 | 2 | 3 | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IMPLANT SITE | 1 | 2 | 3 | 4 | 5 | 1 | 2 | 3 | 4 | 5 | 1 | 2 | 3 | 4 | 5 |
| INFLAMMATION (I) | |||||||||||||||
| 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | |
| 1 | 3 | 0 | 2 | 3 | 3 | 4 | 4 | 4 | 4 | 1 | 2 | 0 | 0 | 3 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| 1 | 3 | 2 | 0 | 3 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 2 | |
| 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 2 | 2 | 0 | 1 | 0 | 0 | 0 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Table 10. Biocompatibility Test Results
| Test | Result |
|---|---|
| Cytotoxicity | Non-cytotoxic |
| Intracutaneous Reactivity | Non-irritant |
| Acute Systemic Toxicity | Non-toxic |
| Sub-acute Toxicity | Non-toxic |
| Sub-chronic Toxicity | Non-toxic |
| Hemolysis | Non-hemolytic |
| Material Mediated Pyrogenicity | Non-pyrogenic |
| Genotoxicity: Reverse Mutation | Non-mutagenic |
| Genotoxicity: Mouse Lymphoma | Non-mutagenic |
| Intramuscular Implant | Non-irritant |